Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease.

Alzheimers Res Ther · 2019 · PMC6933740 · PMID 31881963

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although not significant, APOE ε4 carriers showed a trend of higher levels of plasma Aβ 1–42 and higher levels of biomarker combinations such as Aβ 1–42 /Aβ 1–40 and Aβ 1–42 xtau than APOE ε4 non-carriers.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.